The spread of antimicrobial resistance among Gram negative
bacteria has dramatically reduced the current therapeutic
opportunities and hampered the perspectives of drug
discovery pipeline. Several unmet needs concerning the
optimal therapeutic approaches to severe infections caused
by the leading multi-drug-resistant GNB are still unresolved,
mainly in relationship with the difficulty in the design of
prospective comparative studies. Therefore a perspective
of how the main resistance patterns and the related infections
can be managed in the absence of more definitive data is
mandatory.